Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures

Abstract
Test procedures for determining a neural stimulation threshold of a patient. In one embodiment, the procedure includes applying a test stimulation signal to the patient and monitoring the patient for a response to the test stimulation signal. The procedure can further include determining a first neural stimulation threshold and calculating a second neural stimulation threshold. The first neural stimulation threshold corresponds to the lowest intensity test stimulation signal that evokes a patient response. The second neural stimulation threshold corresponds to a treatment stimulation signal directed toward affecting a neural activity within the patient.
Description
TECHNICAL FIELD

The present disclosure is related to systems and methods for reducing the likelihood of inducing collateral neural activity while determining threshold parameters for electrically stimulating a region in the cortex or other area of the brain.


BACKGROUND

A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. The neural-functions in some areas of the brain (i.e., the sensory or motor cortices) are organized according to physical or cognitive functions. There are also several other areas of the brain that appear to have distinct functions in most individuals. In the majority of people, for example, the areas of the occipital lobes relate to vision, the regions of the left interior frontal lobes relate to language, and the regions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect.


Many problems or abnormalities with body functions can be caused by damage, disease and/or disorders in the brain. Effectively treating such abnormalities may be very difficult. For example, a stroke is a very common condition that damages the brain. Strokes are generally caused by emboli (e.g., obstruction of a vessel), hemorrhages (e.g., rupture of a vessel), or thrombi (e.g., clotting) in the vascular system of a specific region of the brain, which in turn generally cause a loss or impairment of a neural function (e.g., neural functions related to facial muscles, limbs, speech, etc.). Stroke patients are typically treated using various forms of physical therapy to rehabilitate the loss of function of a limb or another affected body part. Stroke patients may also be treated using physical therapy plus an adjunctive therapy such as amphetamine treatment. For most patients, however, such treatments are minimally effective and little can be done to improve the function of an affected body part beyond the recovery that occurs naturally without intervention.


Neural activity is governed by electrical impulses or “action potentials” generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between −70 and −60 mV. Through chemical connections known as synapses, any given neuron receives from other neurons excitatory and inhibitory input signals or stimuli. A neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials when the integration exceeds a threshold potential. A neural firing threshold may be, for example, approximately −55 mV. Action potentials propagate to the neuron's synapses, where they are conveyed to other neurons to which the neuron is synaptically connected.


The neural activity in the brain can be accordingly influenced by electrical energy that is supplied from a man-made source such as a waveform generator. Various neural functions can thus be promoted or disrupted by applying an electrical current to the cortex or other region of the brain. As a result, researchers have attempted to treat damage, disease and disorders in the brain using electrical or magnetic stimulation signals to control or affect brain functions. One treatment approach, transcranial electrical stimulation (TES), involves placing an electrode on the exterior of the scalp and delivering an electrical current to the brain through the scalp and skull. Another treatment approach, transcranial magnetic stimulation (TMS), involves producing a high-powered magnetic field adjacent to the exterior of the scalp over an area of the cortex. Yet another treatment approach involves direct electrical stimulation of neural tissue using implanted electrodes.


A neural stimulation signal may comprise a series or train of electrical or magnetic pulses that can affect neurons within a target neural population, and may be defined or described in accordance with stimulation signal parameters including pulse amplitude, pulse frequency, duty cycle, stimulation signal duration, and/or other parameters. Electrical or magnetic stimulation signals applied to a population of neurons can depolarize neurons within the population toward their threshold potentials. Depending upon stimulation signal parameters, this depolarization can cause neurons to generate or fire action potentials. Neural stimulation that elicits or induces action potentials in a functionally significant proportion of the neural population to which the stimulation is applied is referred to as supra-threshold stimulation; neural stimulation that fails to elicit action potentials in a functionally significant proportion of the neural population is defined as sub-threshold stimulation. In general, supra-threshold stimulation of a neural population triggers or activates one or more functions associated with the neural population, but sub-threshold stimulation by itself fails to trigger or activate such functions. Supra-threshold neural stimulation can induce various types of measurable or monitorable responses in a patient. For example, supra-threshold stimulation applied to a patient's motor cortex can induce muscle fiber contractions.


Although electrical or magnetic stimulation of neural tissue may be directed toward producing an intended type of therapeutic, rehabilitative, or restorative neural activity, such stimulation may result in collateral neural activity. In particular, neural stimulation delivered beyond a certain intensity, level, or amplitude can give rise to seizure activity and/or other types of collateral activity, which may be undesirable and/or inconvenient in a neural stimulation situation.


Seizure activity may originate at a seizure focus, which is a collection of neurons (e.g., on the order of 1000 neurons) exhibiting a characteristic type of synchronous firing activity. In particular, each neuron within a seizure focus exhibits a firing response known as a paroxysmal depolarizing shift (PDS). The PDS is a large magnitude, long duration depolarization that triggers a neuron to fire a train or burst of action potentials. Properly functioning feedback and/or feed-forward inhibitory signaling mechanisms cause an ensuing afterhyperpolarization, through which the neuron's membrane potential returns to a hyperpolarized state below its firing threshold. Following the afterhyperpolarization, the neuron may undergo another PDS.


The afterhyperpolarization limits the duration of the PDS, thereby helping to ensure that synchronous neural firing activity remains localized to the seizure focus. Inhibitory feedback signaling provided by neurons surrounding a seizure focus, commonly referred to as surround inhibition, is particularly important in constraining seizure activity to the seizure focus. In the event that inhibitory signaling mechanisms fail and/or are unable to overcome or counter PDS activity, neurons within the seizure focus recruit other neurons to which they are synaptically coupled into their synchronous firing pattern. As a result, synchronous firing activity spreads beyond the seizure focus to other areas of the brain. This can lead to a cascade effect in which seizure activity becomes increasingly widespread and accompanying clinical manifestations become increasingly significant.


In view of the foregoing, it may be very important in any given neural stimulation situation to determine an appropriate stimulation signal amplitude, level, or intensity. However, an appropriate stimulation signal level may vary on a per-patient basis and possibly over time for any particular patient. Notwithstanding, determination of a neural stimulation threshold corresponding to a minimum or near-minimum stimulation signal level that induces or generates a measurable or monitorable patient response can provide a reference point for establishing a stimulation signal intensity appropriate for a neural stimulation session.


Various types of neural stimulation thresholds exist. For example, an electromyography or electromyographic (EMG) threshold may be defined as a lowest or near-lowest level of neural stimulation that generates an EMG signal of a particular magnitude. An EMG signal provides a measurement of electrical discharges associated with the innervation of muscle fibers by one or more motor neurons, and the onset of muscle fiber contraction in response to such electrical discharges. As another example, a sensation threshold may be defined as a lowest or near-lowest level of neural stimulation at which a patient notices, perceives, or experiences a physical sensation such as a tingling or vibration in a muscle group or limb. As yet another example, a movement threshold may be defined as a lowest or near-lowest level of neural stimulation that induces a noticeable movement in a patient's limb.


Unfortunately, neural stimulation threshold testing can itself induce collateral neural activity. During a typical neural stimulation threshold test procedure, a very low amplitude test stimulation signal is initially applied to a patient. The amplitude of the test stimulation signal is then increased incrementally, while other test stimulation signal parameters (e.g., frequency, pulse characteristics, duty cycle, etc . . . ) remain unchanged or unmodified. As its amplitude is increased, the test stimulation signal is delivered to the patient in an uninterrupted or continuous manner. A lowest or near-lowest test stimulation signal amplitude that evokes a given type of patient response is correspondingly defined as the neural stimulation threshold. The patient is subsequently treated using a stimulation signal having parameters identical to those of the test stimulation signal, with the possible exception of stimulation signal amplitude, which may be a predetermined value based on the neural stimulation threshold.


Stimulation signal characteristics and manners in which stimulation signals are applied to a target neural population can significantly affect the likelihood of inducing collateral neural activity. Conventional neural stimulation threshold test procedures fail to adequately address this consideration, and thus may be susceptible to inducing seizure activity and/or other types of collateral neural activity. Hence, there is a need for systems and methods that reduce the likelihood of inducing such activity during neural stimulation threshold testing.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic illustration of a system for neural stimulation threshold testing according to an embodiment of the invention.



FIG. 2 is a graph illustrating several parameters that may describe or characterize a stimulation signal.



FIG. 3 is a flowchart illustrating various methods for neural stimulation threshold testing according to an embodiment of the invention.



FIG. 4 is a flowchart illustrating various methods for neural stimulation threshold testing according to another embodiment of the invention.





DETAILED DESCRIPTION

The following disclosure describes systems and methods for reducing the likelihood of inducing collateral neural activity during the application of test stimulation signals to a patient for the purpose of determining a threshold stimulation level that induces or evokes a particular type of patient response, behavior, activity, sensation, perception, and/or reaction. In the context of the present invention, collateral neural activity may comprise seizure activity and/or essentially any other type of neural activity that may be undesirable, unwanted, unintended, and/or counterproductive relative to an intended or desired neural activity associated with neural stimulation threshold testing.


Various methods in accordance with the present invention are directed toward neural stimulation threshold test procedures that temporally manage the application of test stimulation signals to a patient. Neural stimulation lasting beyond several seconds (e.g., approximately 5 seconds) can lead to prolonged neural firing responses known as afterdischarges. Afterdischarges in a target neural population increase or tend to increase neural activity in the population, which may excite other neurons synaptically coupled to the target population. Afterdischarges can therefore increase the likelihood of inducing collateral neural activity. Neural stimulation threshold test procedures in accordance with the present invention may therefore apply limited duration test stimulation signals to patients.


Neural stimulation applied to a target neural population can affect the future excitability or firing likelihood of neurons in the target population. In particular, recently stimulated neurons may exhibit enhanced excitability in the presence of subsequent stimulation. A neural population that receives sub-threshold stimulation during a first time period may exhibit an increased firing susceptibility in the presence of same stimulation applied during a second time period when the second time period and the first time period are separated by only a brief interval (e.g., seconds or several seconds). Moreover, neural activity, such as afterdischarges, may persist for many milliseconds or seconds after a stimulation signal is interrupted or terminated. Hence, neural stimulation threshold test procedures in accordance with the present invention may additionally or alternatively provide for a quiescent time interval between successive threshold determination attempts during which test stimulation signals are not applied or delivered to the target neural population.


Various methods in accordance with the present invention may additionally or alternatively be directed toward neural stimulation threshold test procedures in which test stimulation signals and a treatment stimulation signal used to treat a patient may parametrically differ beyond their amplitudes. For example, depending upon stimulation signal parameters, neurons within a target population may respond to a stimulation signal in a synchronous manner. In particular, the ability of neurons to synchronously respond to or follow a stimulation signal is a function of the stimulation signal's frequency. Neurons can readily follow a stimulation signal up to a frequency of approximately 100 Hertz, but beyond this frequency their ability to follow the stimulation signal degrades. Supra-threshold stimulation delivered to a target neural population at a frequency that-neurons can readily follow may drive synchronous firing activity within the population. In view of the foregoing, a neural stimulation threshold test procedure in accordance with the present invention may measure a first neural stimulation threshold using one or more test stimulation signals having a first frequency; and subsequently calculate a second neural stimulation threshold corresponding to a treatment stimulation signal that may have a second frequency different from the first frequency. The calculation of the second neural stimulation threshold may be performed in accordance with one or more transformation equations, as described in detail below.



FIG. 1 is a schematic illustration of a system 100 for neural stimulation threshold testing according to an embodiment of the invention. In one embodiment, the system 100 comprises a stimulus unit 120 configured to deliver stimulation signals to a patient 190 through a patient interface 109. The system 100 may further include a sensing unit 180 coupled to the patient 190 and the stimulus unit 120.


The stimulus unit 120 is capable of generating and outputting stimulation signals, which comprise electrical and/or magnetic signals or stimuli. The stimulus unit 120 may perform, direct, and/or facilitate neural stimulation threshold test procedures in a manner that reduces the likelihood of inducing collateral neural activity in accordance with the present invention. Neural stimulation threshold test procedures may involve the application of one or more test stimulation signals to a patient 190 in manners described in detail below. The stimulus unit 120 may additionally perform, direct, and/or facilitate neural stimulation treatment procedures to treat a particular neurological condition and/or affect or influence a given type of neural activity. Neural stimulation treatment procedures involve the application of a treatment stimulation signal to a patient. The treatment stimulation signal, for example, is typically at a level or amplitude that corresponds to a result obtained during neural stimulation threshold test procedures (e.g., 20% to 80% of a neural stimulation threshold).


The stimulus unit 120 may comprise a controller 130, a pulse system 140, and a set of controls/indicators 150. The controller 130 may include a processor, a memory, and a programmable computer medium. The controller 130 may be implemented as a computer or microcontroller, where the programmable medium comprises software loaded into the memory, and/or hardware that performs, directs, and/or facilitates neural stimulation threshold test procedures in accordance with the methods of the present invention. The controls/indicators 150 can include a display device, an input/output device, and/or other types of devices for exchanging commands and/or output with a computer.


The pulse system 140 can generate energy pulses, and send such pulses to the patient interface 109. In one embodiment, the pulse system 140 forms a portion of a Transcranial Magnetic Stimulation (TMS) device through which externally applied magnetic stimulation signals create electrical currents in the patient's brain. In such an embodiment, the patient interface 109 may comprise an electromagnetic coil arrangement in a manner understood by those skilled in the art. In another embodiment, the pulse system 140 forms a portion of an electrical stimulation device; in this case the patient interface 109 may comprise an electrode array configured to deliver electrical stimulation signals to the patient 190 as described in detail hereafter.


The patient interface 109 shown in FIG. 1 comprises an electrode array 110 including a support member 112 and a plurality of electrodes 114 carried by the support member 112. The electrode array 110 is generally implanted into the patient 190 and configured for cortical stimulation, deep brain stimulation, and/or other types of neural stimulation. The electrode array 110 may comprise a cortical neural-stimulation device, such as a device described in U.S. application Ser. No. 09/802,808, incorporated herein by reference. The electrodes 114 may be coupled to the stimulus unit 120 by a link 116, which may be wire-based or wireless.


The electrode array 110 and the pulse system 140 can be integrated into a single implantable stimulation apparatus, as described in U.S. application Ser. No. 09/082,808. An integrated pulse system 140 and electrode array 110 may be configured for implantation into a patient's skull such that the electrodes 114 can contact the patient's dura matter or pia matter in a given cortical region. Such a device can have an internal power source that can be implanted into the patient 190, and/or an external power source coupled to the pulse system 140 via electromagnetic coupling or a direct connection. In alternate embodiments, the pulse system 140 is an external unit that is not implanted into the patient 190. An external pulse system 140 can provide stimuli to the electrodes 114 using RF energy, electromagnetism, or wire terminals exposed on the patient's scalp.


The sensing unit 180 may comprise a system or apparatus for measuring or monitoring one or more types of patient reactions evoked or induced in response to test stimulation signals applied during neural stimulation threshold test procedures. The sensing unit 180 can be coupled to the stimulus unit 120 by at least one link 186, which may be wire-based and/or wireless. The stimulus unit 120 may issue a signal over the link 186 to synchronize the application of test stimulation signals to the patient 190 with sensing unit measuring, monitoring, and/or recording operations. Depending upon embodiment details, the sensing unit 180 may also use the link 186 to communicate status information and/or measurement results to the stimulus unit 120.


In one embodiment, the sensing unit 180 comprises an EMG device coupled to a plurality of electrodes or leads 182. The EMG device may detect or monitor motor evoked potentials (MEPs) associated with muscle fiber innervation in a manner understood by those skilled in the art. An EMG threshold may be defined, for example, as a lowest or near-lowest level of neural stimulation that induces an MEP that departs from baseline electrical activity by an amplitude greater than 50 microvolts peak-to-peak under 1000× amplification and 20-1000 Hertz bandpass conditions. The electrodes 182 may comprise surface, percutaneous, and/or implanted probes, which may be positioned or configured to measure electrical activity associated with one or more muscles or muscle groups. In one embodiment, the electrodes 182 include a ground lead and bipolar surface leads configured to monitor MEPs in an interosseus muscle, a wrist extensor, a wrist flexor, and/or other muscles.


Various embodiments of the present invention may alternatively or additionally detect or determine other types neural stimulation thresholds, such as a sensation threshold, a movement threshold, an Electroencephalogram (EEG) threshold, a Magnetoencephalogram (MEG) threshold, and/or an imaging threshold. The structure and/or function of the sensing unit 180 may correspond to the type of neural stimulation threshold under consideration. For example, to facilitate detection of a movement threshold, the sensing unit 180 may comprise a set of motion detectors, accelerometers, and/or strain gauges configured to detect or monitor one or more types of patient movements. To detect or determine an EEG threshold, the sensing unit 180 may comprise an EEG system configured to monitor changes in a patient's EEG during neural stimulation threshold test procedures. Such an EEG system may include and/or utilize electrodes positioned upon the patient's scalp, and/or intracranially upon a brain surface or in a subcortical region.


To detect or determine an MEG threshold, the sensing unit 180 may comprise an MEG system configured to monitor variations in the patient's MEG in response to test stimulation signals. To measure or determine an imaging threshold, the sensing unit 180 may comprise a neural imaging system configured to monitor and image a patient's neural activity during neural stimulation threshold test procedures. Suitable neural imaging systems include Magnetic Resonance Imaging (MRI) systems, functional MRI (fMRI) systems, or Positron Emission Tomography (PET) systems.


Different types of neural stimulation thresholds may vary with respect to measurement or observation subjectivity, and/or sensitivity to stimulation signal intensity. In general, determination of an EMG threshold may be a less subjective process than determination of a movement threshold, which may be a less subjective process than determination of a sensation threshold. Also, an EMG threshold may be triggered or induced at a lower stimulation signal intensity than a sensation or a movement threshold. In general, a sensation threshold may be triggered or induced at a lower stimulation signal intensity than a movement threshold, although this need not always be the case. Determination of movement and/or sensation thresholds may involve or rely upon human perception and verbal and/or visual feedback, and may not require the use of a sensing unit 180.


As previously indicated, the stimulus unit 120 is configured to deliver stimulation signals to a patient 190; the stimulation signals may comprise test stimulation signals and/or treatment stimulation signals. FIG. 2 is a graph illustrating several parameters that may define, describe, or characterize stimulation signals. A stimulus start time t0 defines an initial point at which a stimulation signal is applied to the patient interface 110. In one embodiment, the stimulation signal may be a biphasic waveform comprising a series of biphasic pulses, and which may be defined, characterized, or described by parameters including a pulse width t1 for a first pulse phase; a pulse width t2 for a second pulse phase; and a pulse width t3 for a single biphasic pulse. The parameters can also include a stimulus repetition rate 1/t4 corresponding to a pulse repetition frequency; a stimulus pulse duty cycle equal to t3 divided by t4; a stimulus burst time t5 that defines a number of pulses in a pulse train; and/or a pulse train repetition rate 1/t6 that defines a stimulus burst frequency. Other parameters include a peak current intensity 11 for the first pulse phase and a peak current intensity I2 for the second pulse phase. Those skilled in the art will understand that pulse intensity or amplitude may decay during one or both pulse phases, and a pulse may be a charge-balanced waveform. Those skilled in the art will further understand that in an alternate embodiment, pulses can be monophasic or polyphasic.



FIG. 3 is a flowchart illustrating various methods for neural stimulation threshold testing according to an embodiment of the invention. In one embodiment, a method 300 may include a parameter determination procedure 302 involving determination, selection, or specification of test stimulation signal parameters that may reduce a likelihood of inducing collateral neural activity. Depending upon embodiment details, one or more types of test stimulation signal parameter sets, selections, and/or settings may be preprogrammed into the stimulus unit 120. A stimulus unit operator (e.g., a medical professional) may select a particular set of test stimulation signal parameters using the stimulus unit's controls/indicators 150. Exemplary test stimulation signal parameter selections that may reduce the likelihood of inducing collateral neural activity are described in detail below with reference to FIG. 4.


The method 300 may additionally include a signal management procedure 304 that involves managing the temporal application of test stimulation signals to a patient 190 in a manner that reduces the likelihood of inducing collateral neural activity. A stimulus unit operator may use the stimulus unit's controls/indicators 150 to initiate the signal management procedure 304. Particular manners of temporally managing test stimulation signal application in accordance with the present invention are described in detail below with reference to FIG. 4. The method 300 may additionally include an observation or measurement procedure 306 that involves observing and/or measuring one or more neural stimulation thresholds based upon one or more patient reactions and/or behaviors induced in response to the test stimulation signals. The observation procedure 306 may be performed using the sensing unit 180 and/or human perception and feedback.


The method 300 may further include a calculation procedure 308 involving calculation, mapping, and/or determination of a neural stimulation threshold corresponding to a treatment stimulation signal that is to be applied to the patient 190 for treating a neurological condition and/or affecting neural activity. The treatment stimulation may be parametrically distinct from one or more test stimulation signals with respect to one or more parameters. Operations performed and/or directed by the calculation procedure 308 may be based upon one or more measured and/or observed neural stimulation thresholds. The calculation procedure 308 may involve the use of one or more conversion or mapping functions and/or data tables stored in a memory of the stimulation unit. Such functions and/or data tables may be based upon known relationships and/or one or more empirical measurement histories capable of correlating test stimulation signal parameters with treatment stimulation signal parameters for a range of neural stimulation thresholds as measured or observed in association with the observation procedure 306.



FIG. 4 is a flowchart illustrating various methods for neural stimulation threshold testing according to another embodiment of the invention. In one embodiment, a method 400 includes a parameter determination procedure 402 that involves determining, specifying, and/or selecting test stimulation signal parameters that may reduce a likelihood of inducing collateral neural activity. In one embodiment, the pulse repetition frequency within a test stimulation signal may be higher than that within a treatment stimulation signal in order to reduce or minimize the likelihood that a significant number of neurons within a target neural population can synchronously respond to or follow the test stimulation signal. In general, a test stimulation signal needs to activate few or relatively few neurons within a target population to invoke or elicit a measurable and/or observable patient response. Thus, the pulse repetition frequency of a test stimulation signal may be higher than a neural frequency that produces a significant degradation in behavior or function (e.g., above approximately 100 Hertz), without adversely affecting the likelihood that a sufficient number of neurons can fire and evoke a patient response. In accordance with the present invention, exemplary test stimulation signal pulse repetition frequencies may be approximately 250 Hertz to approximately 400 Hertz, and in particular at the endpoints of this range.


An average amount of electrical current, charge, or energy delivered to a target neural population increases with increasing pulse repetition frequency, given constant or essentially constant test stimulation signal duration. As a result, a test stimulation signal having a higher pulse repetition frequency may be expected to elicit or evoke a measurable and/or observable patient response at a lower current level than an equivalent duration test stimulation signal having a lower pulse repetition frequency.


The method 400 may further include a signal application procedure 404 that involves application or initiation of application of (a) a first limited duration test stimulation signal having a low or very low intensity or amplitude to a target neural population within the patient 190; or (b) a next limited duration test stimulation signal having an incrementally or slightly higher intensity or amplitude than a previous test stimulation signal to the target neural population. The use of limited duration test stimulation signals may reduce or minimize the likelihood of generating prolonged neural firing responses such as afterdischarges that can increase neural excitation outside of the target population to which the test stimulation signals are applied. In general, a limited duration test stimulation signal in accordance with the present invention may be shorter than approximately 5 seconds.


The duration of a test stimulation signal applied in accordance with the present invention may depend upon a type of neural stimulation threshold currently under consideration. Thus, a limited duration test stimulation signal applied when determining one type of threshold may be shorter or longer than a limited duration test stimulation signal applied when determining another type of threshold. In general, a shorter duration test stimulation signal may deliver a lower average amount of electrical current, charge, or energy to the target neural population than a longer duration test stimulation signal given equivalent or generally equivalent pulse repetition frequencies. Hence, a shorter duration test stimulation signal may require a higher electrical current intensity, level, or amplitude to induce or evoke a given type of patient response.


With respect to determination of a movement threshold, a shorter duration test stimulation signal may evoke or induce a sharper, better defined, and hence more easily observable patient movement than a longer duration test stimulation signal. With respect to sensation threshold determination, the duration of a test stimulation signal may need to be sufficient to enable a patient 190 to accurately perceive and/or confirm perception of an induced sensation. Thus, in one embodiment, the signal application procedure 404 may apply test stimulation signals lasting at least approximately 1 second or less when the method 400 involves determination of a movement threshold; and/or apply test stimulation signals lasting approximately 3 seconds when the method 400 involves determination of a sensation threshold.


An EMG threshold may be determined in accordance with a variety of EMG measurement and/or EMG signal analysis techniques. The signal application procedure 404 may apply test stimulation signals having a duration corresponding to an EMG measurement and/or EMG signal analysis technique currently under consideration. In accordance with the signal application procedure 404, the stimulus unit 120 may issue a synchronization signal to the sensing unit 180 coincident or essentially coincident with the output of a test stimulation signal to initiate EMG signal monitoring or recording operations in a manner understood by those skilled in the art.


In one embodiment, the signal application procedure 404 may apply test stimulation signals to the patient 190 lasting approximately several milliseconds or on the order of tens of milliseconds when the sensing unit 180 is configured for EMG threshold measurement. An exemplary test stimulation signal duration corresponding to EMG threshold determination may be approximately 16 milliseconds. In such an embodiment, the signal application procedure 404 may repeat the application of a given test stimulation signal to the patient 190 multiple times to increase an EMG signal to noise ratio (i.e., to average out noise); repeated applications of the test stimulation signal may be separated by a minimum quiescent time interval as further described below. The determination of an EMG threshold using test stimulation signals having a duration on the order of milliseconds or tens of milliseconds may performed in a manner analogous or generally analogous to conventional nerve conduction studies. In another embodiment, the signal application procedure 404 may apply test stimulation signals to the patient 190 lasting approximately 1 second to 3 seconds.


In addition to the signal application procedure 404, the method 400 may include a monitoring procedure 406 that involves monitoring or observing the patient 190 and determining whether a patient behavior or reaction has been evoked or induced in response to the most recently applied test stimulation signal. The monitoring procedure 406 may involve the sensing unit 180 and/or human perception and feedback. In the event that the method 400 involves determination of an EMG threshold, the monitoring procedure 406 may record and/or measure an EMG response during one or more portions of a test stimulation and/or throughout its entirety. The monitoring procedure 406 may additionally or alternatively perform EMG signal analysis operations to enhance MEP detectability. Such EMG signal analysis operations may include determination of changes in MEP firing or activation rates, determination of changes in MEP activation complex durations or temporal widths, root-mean-square (RMS) amplitude analysis, power spectrum analysis, correlation analysis, and/or one or more other statistical analyses.


The method 400 may also include an adjustment procedure 408 involving modification or adjustment of test stimulation signal intensity or amplitude if no patient response was evoked in association with the signal application procedure 404. In the absence of an evoked response, test stimulation signal intensity may be increased in accordance with a particular increment, for example, by 0.5 or 1.0 milliamps, or by a given percentage. The method 400 may additionally include a waiting procedure 410 involving waiting or pausing for a minimum quiescent time interval following application of a most recent test stimulation signal to the patient 190. After the minimum quiescent time interval has elapsed, the method 400 may return to the signal application procedure 404.


The use of a minimum quiescent time interval after the application of a given limited duration test stimulation signal may reduce or minimize the likelihood that neurons within the target neural population will have an increased firing susceptibility or re-excitation likelihood during application of a subsequent test stimulation signal. A minimum quiescent time interval may range from several seconds to several minutes. In an exemplary embodiment, the minimum quiescent time interval is approximately 1 minute. In an alternate embodiment, the minimum quiescent time interval may be shortened or increased depending upon a cumulative number of test stimulation signals that had been applied to the patient 190.


The method 400 may additionally include a threshold measurement procedure 420 involving measurement or determination of a neural stimulation threshold corresponding to the most recently applied test stimulation signal that evoked or induced a patient reaction or response. In one embodiment, the neural stimulation threshold corresponding to a given test stimulation signal is the electrical current level, intensity, or amplitude at which the test stimulation signal evoked or induced a particular type of patient response.


The method 400 may further include a threshold calculation procedure 422 involving calculation of a neural stimulation threshold corresponding to a treatment stimulation signal to be applied to the patient. In calculating a neural stimulation threshold corresponding to a treatment stimulation signal, the threshold calculation procedure 422 may use one or more transformation formulas and/or conversion relationships, which may be programmably stored within the stimulus unit 120. Such transformation formulas and/or conversion relationships may be based upon known parameter relationships and/or empirical data measured across a variety of test stimulation signal parameter configurations, and they may be generated using curve fitting and/or numerical modeling procedures. In one embodiment, a transformation formula appropriate for test stimulation signals and treatment stimulation signals approximately 3 seconds or longer in duration may be of the following general form:

I2(f2)=I1(f)*(1+k*(f1**q))/((1+k*(f2**q))   [1]


In the above equation, I2 may be a peak, average, or RMS current level that defines or establishes a calculated neural stimulation threshold corresponding to the treatment stimulation signal; f2 is a pulse repetition frequency associated with the treatment stimulation signal; I1 is a measured neural stimulation threshold corresponding to a test stimulation signal; f1 is a pulse repetition frequency corresponding to this test stimulation signal; and k and q are constants. The values of k and q may depend upon the nature of the test stimulation signals and/or the treatment stimulation signal. In an exemplary embodiment, for anodic monopolar test stimulation signals, k and q may respectively equal −0.9637 and 0.0249. For bipolar test stimulation signals, k and q may respectively equal −1.0047 and 0.0032.


The above conversion formula may scale linearly, quasi-linearly, or nonlinearly for test stimulation signal durations shorter than 3 seconds; the manner of scaling may depend upon how closely a test stimulation signal's duration approaches 3 seconds. In general, those skilled in the art will understand that additional and/or other types of transformation formulas may be defined, derived, and/or determined in accordance with particular test and/or treatment stimulation signal parameter characteristics under consideration.


A calculated neural stimulation threshold may be larger or smaller than the measured or observed neural stimulation threshold, depending upon test stimulation signal parameters and treatment stimulation signal parameters. The treatment signal may be parametrically distinct from the test stimulation signals; in particular, the treatment stimulation signal may have a different (e.g., lower) pulse repetition frequency and/or a longer (possibly continuous) duration than the test stimulation signals. The treatment stimulation signal may be delivered to the target neural population at an intensity, level, or amplitude that is a particular function or fraction of the calculated neural stimulation threshold.


Various methods for neural stimulation threshold testing in accordance with the present invention may employ additional, fewer, and/or other procedures than those described above. For example, test stimulation signals may differ from a treatment stimulation signal with respect to additional or other parameters than those described above. As another example, a procedure may include a step of verifying a calculated neural stimulation threshold by applying a treatment stimulation signal to the patient 190 at the calculated threshold, and determining whether a patient reaction occurs that is equivalent or generally equivalent to that which occurred during test stimulation signal application. A procedure may also record and store event information, data, and/or measurements obtained during test stimulation signal application. The disclosure herein provides for these and other variations, and is limited only by the following claims.

Claims
  • 1. A neuro-stimulation system for a patient, comprising: an electrode array having an implantable support member configured to be implanted into a patient and a plurality of therapy electrodes carried by the support member,a pulse system operatively coupled to the therapy electrodes, the pulse system delivering a stimulus to the therapy electrodes; anda controller operatively coupled to the pulse system, the controller including a computer operable medium containing instructions that generate command signals that define the stimulus delivered by the pulse system and determine a desired configuration for the therapy electrodes and/or a desired stimulus to be delivered to the therapy electrodes based upon feedback input to the controller, wherein (i) the feedback input reflects a measure of motor activity of the patient and (ii) the control employs a curve fitting operation to adjust stimulation parameters when operation of the pulse system is changed from a first frequency to a second frequency.
  • 2. The system of claim 1 wherein the therapy electrodes are independently coupled to the pulse system such that the pulse system can activate and/or deactivate individual therapy electrodes.
  • 3. The system of claim 1 wherein the pulse system and the electrode array are components of an integrated unit configured to be implanted in the patient at a stimulation site.
  • 4. The system of claim 1 wherein the electrode array is configured to be implanted at a stimulation site in the patient and the pulse system is separate from the electrode array and configured to be implanted at a site in the patient remote from the stimulation site, and the pulse system being coupled to the electrode array by a conductive line implanted in the patient.
  • 5. The system of claim 1 wherein the controller is configured to be external to the patient and the pulse system is configured to be implanted in the patient, and wherein the pulse system is linked to the controller via a direct link or an indirect link such that the controller can direct the pulse system to activate and/or deactivate the electrodes independently.
  • 6. The system of claim 1, further comprising a sensing device configured to be attached to a sensing location of the patient, the sensing device generating response signals defining the feedback input into the controller; and wherein the computer operable medium contains instructions that evaluate the response signals from the sensing device.
  • 7. The system of claim 6 wherein the sensing device comprises a sense electrode configured to be attached to the patient at a sense location to sense a response to the stimulus applied to the therapy electrodes.
  • 8. The system of claim 6 wherein the sensing device comprises a sense electrode configured to be attached to the patient at a sense location and an EMG unit coupled to the sense electrode.
  • 9. The system of claim 6 wherein the sensing device comprises a functional MRI device that detects locations of neural-activity in the brain.
  • 10. The system of claim 6 wherein the computer operable medium of the controller comprises a computer readable medium containing instructions causing the controller to perform the following method: applying an electrical stimulus having a plurality of stimulus parameters to a selected configuration of the therapy electrodes;sensing a response to the applied electrical stimulus using the sensing device;determining whether the response is within a desired range or an improvement over a previous sensed response from a different electrical stimulus and/or a different configuration of therapy electrodes;selecting an alternate configuration of the therapy electrodes and/or an alternate electrical stimulus;repeating the applying, sensing, determining and selecting procedures using the alternate configuration of the therapy electrodes and/or the alternate electrical stimulus; andchoosing a configuration of therapy electrodes and/or an electrical stimulus corresponding to a sensed response that is within a desired range and/or is an improvement compared to other sensed responses.
  • 11. The system of claim 6 wherein the computer operable medium of the controller comprises a computer readable medium containing instructions causing the controller to perform the following method: sending a command signal from the controller to the pulse system;delivering an electrical pulse from the pulse system to a configuration of the therapy electrodes;sensing a response to the electrical pulse using the sensing device;receiving a response signal from the sensing device at the controller,in the controller, determining whether the signal is within a desired range or an improvement over a previous response signal from another electrical pulse and/or another configuration of the therapy electrodes, and selecting an alternate configuration of the therapy electrodes and/or an alternate electrical pulse;repeating the sending, delivering, sensing, receiving, and determining procedures using the alternate configuration of therapy electrodes and/or the alternate electrical pulse; andin the controller, identifying an effective pulse therapy electrode configuration and/or electrical pulse; andstoring the effective therapy electrode configuration and/or electrical parameter in a memory of the controller.
  • 12. The system of claim 6 wherein the computer operable medium of the controller comprises a computer readable medium containing instructions causing the controller to perform the following method: installing the electrode array at a therapy site of a patient;installing the sensing device at a sense location of the patient;selecting a setup configuration of the therapy electrodes and a control stimulus of electrical parameters;applying the control stimulus to the therapy electrodes;sensing a response in the patient with the sensing device and generating a response signal;in the controller, evaluating the response signal by comparing the response signal with at least one of a desired response signal and/or an antecedent response signal sensed by the sensing device that have been stored in a memory of the controller;in the controller, automatically choosing an alternate configuration of therapy electrodes according to the evaluation of the response signal with the desired response signal and/or the antecedent response signal;reapplying the control stimulus to the alternate configuration of therapy electrodes and sensing a response signal using the sensing device; andrepeating the evaluating, choosing and reapplying procedures until the response signal is within a desired range and/or a desired number of therapy electrode configurations have been tested.
  • 13. The system of claim 6 wherein the computer operable medium of the controller comprises a computer readable medium containing instructions causing the controller to perform the following method: installing the electrode array at a therapy site of a patient;installing the sensing device at a sense location of the patient;applying an electrical stimulus having a plurality of stimulus parameters to a control configuration of therapy electrodes;sensing a response in the patient with the sensing device and generating a response signal;in the controller, evaluating the response signal by comparing the response signal with at least one of a desired response signal and/or an antecedent response signal sensed by the sensing device stored in a memory of the controller;in the controller, automatically choosing an alternate set of stimulus parameters according to the evaluation of the response signal with the desired response signal and/or the antecedent response signal;reapplying the alternate set of stimulus parameters to the setup configuration of therapy electrodes and sensing a response signal using the sensing device; andrepeating the evaluating, choosing and reapplying procedures until the response signal is within a desired range and/or a desired number of stimulus parameters have been tested.
  • 14. The system of claim 6 wherein the computer operable medium of the controller comprises a computer readable medium containing instructions causing the controller to perform the following method: selecting an initial set of stimulation parameters for an initial electrical stimulus;applying the initial electrical stimulus to a configuration of the therapy electrodes at a target stimulation site of the patient;sensing a response signal at a sensing site of the patient that corresponds to the initial electrical stimulus applied to the therapy electrodes;independently adjusting a current intensity until a threshold electrical stimulus is identified, the threshold electrical stimulus having a threshold current intensity at which a response is first identified in a population of neurons of the target site; andapplying a sub-threshold electrical stimulus to the configuration of therapy electrodes, the sub-threshold electrical stimulus having a current intensity less than the current intensity of the threshold electrical stimulus.
  • 15. In a computer, a method of automatically determining a favorable neuro-stimulation program for a patient, comprising: applying an electrical stimulus having a plurality of stimulus parameters to a selected configuration of the therapy electrodes that have been installed at a target therapy site of a patient;sensing a response to the applied electrical stimulus at a sensing device that has been installed at a sense location of the patient;determining whether the response is within a desired range or an improvement over a previous sensed response from a different electrical stimulus and/or a different configuration of therapy electrodes;selecting an alternate configuration of therapy electrodes and/or an alternate electrical stimulus;repeating the applying, sensing, determining and selecting procedures using the alternate configuration of therapy electrodes and/or the alternate electrical stimulus; andchoosing a configuration of therapy electrodes and/or an electrical stimulus corresponding to a sensed response that is within a desired range and/or provides a better result compared to other sensed responses;wherein the selecting procedure comprises computing an alternate stimulus parameter while maintaining a constant electrode configuration, and wherein computing the alternate stimulus parameter comprises correlating a plurality of different stimuli applied to the constant electrode configuration with corresponding sensed responses to determine a stimulus/response trend and estimating a new stimulus parameter that is expected to improve the efficacy according to the stimulus/response trend.
  • 16. The method of claim 15 wherein the selecting procedure comprises increasing a stimulus parameter when a stimulus/response trend indicates that an increase in the stimulus parameter improves the efficacy of the stimulus.
  • 17. The method of claim 15 wherein the selecting procedure comprises decreasing a stimulus parameter when a stimulus/response trend indicates that a decrease in the stimulus parameter improves the efficacy of the stimulus.
  • 18. The method of claim 15 wherein the applying, sensing, determining, selecting, repeating and choosing procedures are repeated on the same patient within a period not greater than one week.
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a continuation of U.S. application Ser. No. 12/619,188, filed Nov. 16, 2009, now U.S. Pat. No. 8,121,695, which is a continuation of U.S. application Ser. No. 11/388,190, filed Mar. 23, 2006, now U.S. Pat. No. 7,620,456, which is a continuation of U.S. application Ser. No. 10/350,947, filed Jan. 24, 2003, now U.S. Pat. No. 7,024,247, which is a continuation-in-part of U.S. application Ser. No. 09/978,134, filed Oct. 15, 2001, now U.S. Pat. No. 7,305,268, which is a continuation-in-part of U.S. application Ser. No. 09/802,808, filed Mar. 8, 2001, now U.S. Pat. No. 7,010,351, which claims priority to U.S. Provisional Application No. 60/217,981, filed Jul. 13, 2000, the disclosures of which are fully incorporated herein by reference in their entireties.

US Referenced Citations (245)
Number Name Date Kind
2716226 Jonas Aug 1955 A
3628193 Collins Dec 1971 A
3650276 Burghele et al. Mar 1972 A
3918461 Cooper Nov 1975 A
4030509 Heilman et al. Jun 1977 A
4125116 Fischell Nov 1978 A
4140133 Kastrubin et al. Feb 1979 A
4214804 Little Jul 1980 A
4245645 Arseneault et al. Jan 1981 A
4328813 Ray May 1982 A
4340038 McKean Jul 1982 A
4431000 Butler et al. Feb 1984 A
4474186 Ledley et al. Oct 1984 A
4542752 DeHaan et al. Sep 1985 A
4590946 Loeb May 1986 A
4607639 Tanagho et al. Aug 1986 A
4646744 Capel Mar 1987 A
4702254 Zabara Oct 1987 A
4844075 Liss et al. Jul 1989 A
4865048 Eckerson Sep 1989 A
4969468 Byers et al. Nov 1990 A
5002053 Garcia-Rill et al. Mar 1991 A
5024226 Tan Jun 1991 A
5031618 Mullett Jul 1991 A
5054906 Lyons Oct 1991 A
5063932 Dahl et al. Nov 1991 A
5092835 Schurig et al. Mar 1992 A
5121754 Mullett Jun 1992 A
5143089 Alt Sep 1992 A
5169384 Bosniak et al. Dec 1992 A
5184620 Cudahy et al. Feb 1993 A
5215086 Terry, Jr. et al. Jun 1993 A
5224491 Mehra Jul 1993 A
5255678 Deslauriers et al. Oct 1993 A
5263967 Lyons, III et al. Nov 1993 A
5271417 Swanson et al. Dec 1993 A
5282468 Klepinski Feb 1994 A
5299569 Wernicke et al. Apr 1994 A
5304206 Baker, Jr. et al. Apr 1994 A
5314458 Najafi et al. May 1994 A
5358513 Powell, III et al. Oct 1994 A
5358514 Schulman et al. Oct 1994 A
5370672 Fowler et al. Dec 1994 A
5405375 Ayers et al. Apr 1995 A
5406957 Tansey Apr 1995 A
5411540 Edell et al. May 1995 A
5417719 Hull et al. May 1995 A
5423864 Ljungstroem Jun 1995 A
5464446 Dreessen et al. Nov 1995 A
5520190 Benedict et al. May 1996 A
5522864 Wallace et al. Jun 1996 A
5537512 Hsia et al. Jul 1996 A
5540736 Haimovish et al. Jul 1996 A
5549655 Erickson Aug 1996 A
5562708 Combs et al. Oct 1996 A
5575813 Edell et al. Nov 1996 A
5591216 Testerman et al. Jan 1997 A
5593432 Crowther et al. Jan 1997 A
5601611 Fayram et al. Feb 1997 A
5611350 John Mar 1997 A
5628317 Starkebaum et al. May 1997 A
5674251 Combs et al. Oct 1997 A
5676655 Howard, III et al. Oct 1997 A
5683422 Rise Nov 1997 A
5702429 King Dec 1997 A
5711316 Elsberry et al. Jan 1998 A
5713922 King Feb 1998 A
5713923 Ward et al. Feb 1998 A
5716377 Rise et al. Feb 1998 A
5722401 Pietroski Mar 1998 A
5735814 Elsberry et al. Apr 1998 A
5750376 Weiss et al. May 1998 A
5752979 Benabid May 1998 A
5772591 Cram Jun 1998 A
5782798 Rise Jul 1998 A
5782873 Collins Jul 1998 A
5792186 Rise Aug 1998 A
5797970 Pouvreau Aug 1998 A
5814014 Elsberry et al. Sep 1998 A
5814092 King Sep 1998 A
5824021 Rise Oct 1998 A
5824030 Yang et al. Oct 1998 A
5832932 Elsberry et al. Nov 1998 A
5833709 Rise et al. Nov 1998 A
5843148 Gijsbers et al. Dec 1998 A
5843150 Dreessen et al. Dec 1998 A
5865842 Knuth et al. Feb 1999 A
5885976 Sandyk Mar 1999 A
5886769 Zolten Mar 1999 A
5893883 Torgerson et al. Apr 1999 A
5904916 Hirsch May 1999 A
5913882 King Jun 1999 A
5916171 Mayevsky Jun 1999 A
5925070 King et al. Jul 1999 A
5938688 Schiff Aug 1999 A
5938689 Fischell et al. Aug 1999 A
5941906 Barreras, Sr. et al. Aug 1999 A
5964794 Bolz et al. Oct 1999 A
5975085 Rise Nov 1999 A
5978702 Ward et al. Nov 1999 A
5983140 Smith et al. Nov 1999 A
6006124 Fischell et al. Dec 1999 A
6011996 Gielen et al. Jan 2000 A
6016449 Fischell et al. Jan 2000 A
6018682 Rise Jan 2000 A
6021352 Christopherson et al. Feb 2000 A
6026326 Bardy Feb 2000 A
6035236 Jarding et al. Mar 2000 A
6040180 Johe Mar 2000 A
6042579 Elsberry et al. Mar 2000 A
6052624 Mann Apr 2000 A
6055456 Gerber Apr 2000 A
6057846 Sever, Jr. May 2000 A
6057847 Jenkins May 2000 A
6058331 King May 2000 A
6060048 Cherksey May 2000 A
6061593 Fischell et al. May 2000 A
6066163 John May 2000 A
6104956 Naritoku et al. Aug 2000 A
6104960 Duysens et al. Aug 2000 A
6122548 Starkebaum et al. Sep 2000 A
6126657 Edwards et al. Oct 2000 A
6128537 Rise Oct 2000 A
6128538 Fischell et al. Oct 2000 A
6134474 Fischell et al. Oct 2000 A
6152143 Edwards Nov 2000 A
6161044 Silverstone Dec 2000 A
6161045 Fischell et al. Dec 2000 A
6176242 Rise Jan 2001 B1
6198958 Ives et al. Mar 2001 B1
6205360 Carter et al. Mar 2001 B1
6205361 Kuzma et al. Mar 2001 B1
6210417 Baudino et al. Apr 2001 B1
6221908 Kilgard et al. Apr 2001 B1
6230049 Fischell et al. May 2001 B1
6236892 Feler May 2001 B1
6246912 Sluijter et al. Jun 2001 B1
6280462 Hauser et al. Aug 2001 B1
6301493 Marro et al. Oct 2001 B1
6319241 King et al. Nov 2001 B1
6339725 Naritoku et al. Jan 2002 B1
6353754 Fischell et al. Mar 2002 B1
6354299 Fischell et al. Mar 2002 B1
6356792 Errico et al. Mar 2002 B1
6360122 Fischell et al. Mar 2002 B1
6366813 DiLorenzo Apr 2002 B1
6375666 Mische Apr 2002 B1
6405079 Ansarinia Jun 2002 B1
6418344 Rezai Jul 2002 B1
6427086 Fischell et al. Jul 2002 B1
6456886 Howard, III et al. Sep 2002 B1
6459936 Fischell et al. Oct 2002 B2
6463328 John Oct 2002 B1
6464356 Sabel et al. Oct 2002 B1
6466822 Pless Oct 2002 B1
6473568 Kashiyama Oct 2002 B2
6473639 Fischell et al. Oct 2002 B1
6480743 Kirkpatrick et al. Nov 2002 B1
6484059 Gielen Nov 2002 B2
6487450 Chen Nov 2002 B1
6499488 Hunter et al. Dec 2002 B1
6505075 Weiner Jan 2003 B1
6507755 Gozani et al. Jan 2003 B1
6556868 Naritoku et al. Apr 2003 B2
6597954 Pless et al. Jul 2003 B1
6615065 Barrett et al. Sep 2003 B1
6622048 Mann et al. Sep 2003 B1
6633780 Berger Oct 2003 B1
6665562 Gluckman et al. Dec 2003 B2
6687525 Llinas et al. Feb 2004 B2
6690974 Archer et al. Feb 2004 B2
6708064 Rezai Mar 2004 B2
6725094 Saberski Apr 2004 B2
6764498 Mische Jul 2004 B2
6782292 Whitehurst Aug 2004 B2
6795737 Gielen et al. Sep 2004 B2
6810286 Donovan et al. Oct 2004 B2
6839594 Cohen et al. Jan 2005 B2
6873872 Gluckman et al. Mar 2005 B2
6892097 Holsheimer May 2005 B2
6895280 Meadows et al. May 2005 B2
6907296 Doan et al. Jun 2005 B1
6934580 Osorio et al. Aug 2005 B1
6944497 Stypulkowski Sep 2005 B2
6959215 Gliner et al. Oct 2005 B2
6990377 Gliner et al. Jan 2006 B2
7006859 Osorio et al. Feb 2006 B1
7010351 Firlik et al. Mar 2006 B2
7024247 Gliner et al. Apr 2006 B2
7110820 Tcheng et al. Sep 2006 B2
7620456 Gliner et al. Nov 2009 B2
8121695 Gliner et al. Feb 2012 B2
20020087201 Firlik et al. Jul 2002 A1
20020091419 Firlik Jul 2002 A1
20020099412 Fischell et al. Jul 2002 A1
20020169485 Pless et al. Nov 2002 A1
20030074032 Gliner Apr 2003 A1
20030078633 Firlik et al. Apr 2003 A1
20030088274 Gliner et al. May 2003 A1
20030097161 Firlik et al. May 2003 A1
20030114886 Gluckman et al. Jun 2003 A1
20030125772 Olsen et al. Jul 2003 A1
20030125786 Gliner et al. Jul 2003 A1
20030130706 Sheffield et al. Jul 2003 A1
20030149457 Tcheng et al. Aug 2003 A1
20030176901 May Sep 2003 A1
20030187490 Gliner Oct 2003 A1
20030187491 Greenberg et al. Oct 2003 A1
20040073270 Firlik et al. Apr 2004 A1
20040082847 McDermott Apr 2004 A1
20040088024 Firlik et al. May 2004 A1
20040092809 DeCharms May 2004 A1
20040102828 Lowry et al. May 2004 A1
20040111127 Gliner et al. Jun 2004 A1
20040131998 Marom et al. Jul 2004 A1
20040138550 Hartlep et al. Jul 2004 A1
20040158298 Gliner et al. Aug 2004 A1
20040176831 Gliner et al. Sep 2004 A1
20040181263 Balzer et al. Sep 2004 A1
20040215287 Swoyer et al. Oct 2004 A1
20040236388 Gielen et al. Nov 2004 A1
20040243205 Keravel et al. Dec 2004 A1
20040249422 Gliner et al. Dec 2004 A1
20050004620 Singhal et al. Jan 2005 A1
20050015129 Mische Jan 2005 A1
20050021104 DiLorenzo Jan 2005 A1
20050021105 Firlik et al. Jan 2005 A1
20050021106 Firlik et al. Jan 2005 A1
20050021107 Firlik et al. Jan 2005 A1
20050021118 Genau et al. Jan 2005 A1
20050033378 Sheffield et al. Feb 2005 A1
20050070971 Fowler et al. Mar 2005 A1
20050075679 Gliner et al. Apr 2005 A1
20050075680 Lowry et al. Apr 2005 A1
20050096701 Donovan et al. May 2005 A1
20050113882 Cameron et al. May 2005 A1
20050119712 Shafer Jun 2005 A1
20050154425 Boveja et al. Jul 2005 A1
20050154426 Boveja et al. Jul 2005 A1
20060015153 Gliner et al. Jan 2006 A1
20060106430 Fowler et al. May 2006 A1
20060106431 Wyler et al. May 2006 A1
20060129205 Boveja et al. Jun 2006 A1
20060173522 Osorio Aug 2006 A1
20060217782 Boveja et al. Sep 2006 A1
Foreign Referenced Citations (16)
Number Date Country
19750043 May 1999 DE
0319844 Jun 1989 EP
0998958 May 2000 EP
1145736 Oct 2001 EP
1180056 Nov 2003 EP
WO 87-07511 Dec 1987 WO
WO 94-07564 Apr 1994 WO
WO 95-21591 Aug 1995 WO
WO 98-06342 Feb 1998 WO
WO 01-97906 Dec 2001 WO
WO 02-09811 Feb 2002 WO
WO 02-36003 May 2002 WO
WO 02-38031 May 2002 WO
WO 02-38217 May 2002 WO
WO 03-043690 May 2003 WO
WO 03-082402 Oct 2003 WO
Non-Patent Literature Citations (110)
Entry
Gliner, et al., U.S. Appl. No. 60/325,978, filed Sep. 28, 2001.
Firlik, et al., U.S. Appl. No. 60/325,872, filed Sep. 28, 2001.
EPO, International Search Report for Application No. PCT/US2002/32695; Applicant: Vertis Neuroscience, Inc.; Dec. 27, 2002; 9 pgs.
Barr, Deborah et al., “Induction and Reversal of Long-Term Potentiation by Low-and High- Intensity Theta Pattern Stimulation,” The Journal of Neuroscience, 15(7): pp. 5402-5410 (Jul. 1995).
Barres et al., “Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons,” Nature; Medical Research Council Developmental Neurobiology Programme, Department of Biology, University College, London, p. 258-260, (Jan. 21, 1993).
Behrens, T. et al., “Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging,” Nature neuroscience, vol. 6 No. 7, pp. 750-757 (Jul. 2003).
Bel, S. and Bauer, B.L., “Dorsal Column Stimulation (DCS): Cost to Benefit Analysis,” Acta Neurochirurgica, Suppl. 52, pp. 121-123 (1991).
Benabid, A.L. et al., “Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders,” J. Neurosurg., Apr. 1997, 86(4); 737; http:—www.ncbi.nlm.nih.gov; [accessed Nov. 18, 2003].
Bluestone, Avraham Y. et al., “Three-dimensional optical tomography of hemodynamics in the human head,” Optics Express, vol. 9, No. 6, pp. 272-286 (Sep. 10, 2001).
Brain Electrical Stimulation to Enhance Recovery After Stroke, ClinicalTrials.gov, URL: http://www.clinicaltrials.gov/ct/show/NCT00085657?order=2 [Retrieved on Dec. 22, 2005].
Burnett, Mark G. et al., “Diffuse optical measurement of blood flow, blood oxygenation, and metabolism in a human brain during sensorimotor cortex activation,” Optics Letters, vol. 29, No. 15, pp. 1766-1768 (Aug. 1, 2004).
Bury, Scott et al., “The Effects of Behavioral Demand on Motor Cortical and Cerebellar Structural Plasticity After Brain Injury in Adult Rats,” http://www.mcmaster.ca-inabis98-schallert-bury0827-two.html#introduction, 2 pages [Retrieved on Mar. 1, 2003].
Butefisch et al., “Mechanisms of use-dependent plasticity in the human motor cortex,” Proc. Natl. Acad. Sci. USA, vol. 97, No. 7, pp. 3661-3665 (Mar. 2000).
Canavero, S. and Paolotti, R., “Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report,” Movement Disorders, Jan. 2000, 15(1):169-171.
Cao, Yue et al., “Cortical Language Activation in Stroke Patients Recovering From Aphasia With Functional MRI,” Stroke, vol. 30, pp. 2331-2340, Nov. 1999.
Cheun et al., “Differentiation of a Stem Cell Line Toward a Neuronal Phenotype,” Int. J. Devl. Neuroscience, vol. 9, No. 4, pp. 391-404 (1991).
Cincotta et al., “Reorganization of the motor cortex in a patient with congenital hemiparesis and mirror movements,” Neurology, Jul. 12, 2000, 5+A535(1), pp. 129-131.
Classen et al., “Rapid Plasticity of Human Cortical Movement Representation Induced by Practice,” The Journal of Neurophysiology, vol. 79, No. 2, pp. 1117-1123 (Feb. 1998).
Cohen et al., “Studies of Neuroplasticity With Transcranial Magnetic Stimulation,” The Journal of Clinical Neurophysiology, vol. 15, No. 4 (1998).
Cramer, S.C. and Bastings, E.P., “Mapping clinically relevant plasticity after stroke,” Neuropharmacology vol. 19, No. 5, pp. 842-851 (Apr. 2000).
Cytokines Web Clinical Significance, Cytokines Web, 2 pages, URL: http:—cmbi.bjmu.edu.cn-cmbidata-cgf-CGF—Database-cytweb-roles-index.html [Retrieved on Sep. 2, 2005].
Dam et al., “Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy,” Stroke, vol. 27, No. 7, pp. 1211-1214 (Jul. 1996).
De Ridder, Dirk et al., “Magnetic and electrical stimulation of the auditory cortex for intractable tinnitus,” Journal Neurosurg., vol. 100, pp. 560-564, (Mar. 2004).
Di Lazzaro, V. et al., “Theta-burst repetitive transcranial magnetic stimulation suppresses specific excitatory circuits in the human motor cortex,” Physiology in Press; published online on Apr. 21, 2005 as 10.1113-jphysiol.2005.087288.
Ding, Yuemin et al., “Neural Plasticity After Spinal Cord Injury,” Current Pharmaceutical Design vol. 11, No. 11, pp. 1441-1450, Abstract Only, 1 page (Apr. 2005).
Duncan, Pamela W. et al., “Defining post-stroke recovery: implications for design and interpretation of drug trials,” Neuropharmacology vol. 39, pp. 835-841 (2000).
Feys et al., “Value of somatosensory and motor evoked potentials in predicting arm recovery after a stroke,” (Oct. 1999).
Franzini et al., “Reversal of thalamic hand syndrome by long-term motor cortex stimulation,” Journal of Neurosurgery 93(5):873-875, Nov. 2000.
Fregni, Felipe et al., “Anodal Transcranial Direct Current Stimulation of Prefrontal Cortex Enhances Working Memory,” Experimental Brain Research vol. 166, No. 1, pp. 23-30 (Sep. 2005).
Gladstone et al., “Enhancing Recovery after Stroke with Noradrenergic Pharmacotherapy: A New Frontier?” Can J. Neurol. Sci., vol. 27, No. 2, May 2000, pp. 97-105.
Gordon et al., “Parameters for direct cortical electrical stimulation in the human: histopathologic confirmation,” Electroencephalography and clinical Neurophysiology, vol. 75, pp. 371-377 (1990).
Hagemann, Georg et al., “Increased Long-Term Potentiation in the Surround of Experimentally Induced Focal Cortical Infarction,” Annals of Neurology, vol. 44, No. 2, pp. 255-258 (Aug. 1998).
Haglund, Michael M. et al., “Optical imaging of epileptiform and functional activity in human cerebral cortex,” Nature, Aug. 20, 1992, pp. 668-671, vol. 358, Nature Publishing Group.
Hayakawa, Toshiji et al., “Changes in Cerebral Oxygenation and Hemodynamics During Obstructive Sleep Apneas,” Chest, vol. 109, pp. 916-921 (1996).
Hodge, Jr., C.J. and Boakye, M., “Biological Plasticity: The Future of Science in Neurosurgery,” Neurosurgery, vol. 48, No. 1 (Jan. 2001).
Hoshi, Yoko et al., “Detection of dynamic changes in cerebral oxygenation coupled to neuronal function during mental work in a man,” Neuroscience Letters, vol. 150, pp. 5-8 (1993).
Hoshino et al., “Application of multichannel near-infrared spectroscopic topography to physiological monitoring of the cortex during cortical mapping: technical case report,” Surgical Neurology, vol. 64, pp. 272-275 (2005).
How Imagent™ Works. ISS Inc., http://www.iss.com-Products-imagent—fmri.html, 1 page [Retrieved on Oct. 14, 2005].
Huang, Ying-Zu et al., “Theta Burst Stimulation of the Human Motor Cortex,” Neuron, vol. 45, pp. 201-206 (Jan. 20, 2005).
Hummel, Friedhelm et al., “Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke,” Brain Advance Access, pp. 1-10, (Jan. 5, 2005).
Imagent™ Functional Brain Imaging System, ISS, Inc., http://www.iss.com-Products-imagent.html, 2 pages [Retrieved on Oct. 14, 2005].
Imagent™ functional Near Infrared Imaging System (fNIRS) Brain Imaging Using Infrared Photons, ISS Inc., http://www.iss.com-products-imagent-Imagent.pdf, 8 pages [Retrieved on Oct. 14, 2005].
Ishibashi, Tomoko et al., “Astrocytes Promote Myelination in Response to Electrical Impulses,” Neuron 49, pp. 823-832, (Mar. 16, 2006).
Janicek, Milos J. et al., “Dynamic Infrared Imaging of Newly Diagnosed Malignant Lymphoma Compared with Gallium-67 and Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography,” Technology in Cancer Research and Treatment, vol. 2, No. 6, pp. 571-577 (Dec. 2003).
Kauhanen et al., “Domains and Determinants of Quality of Life After Stroke Caused by Brain Infarction,” Arch. Phys. Med. Rehabil., vol. 81, pp. 1541-1546 (Dec. 2000).
Keyvani, Kathy et al., “Suppression of proteasome C2 contralateral to ischemic lesions in rat brain,” Brain Research, vol. 858, pp. 386-392, 2000.
Kilgard, Michael et al., “Cortical Map Reorganization Enabled by Nucleus Basalis Activity,” Science, vol. 279 pp. 1714-1717 (Mar. 13, 1998).
Kopell et al., “The Continuing Evolution of Psychiatric Neurosurgery,” CNS Spectrums, vol. 5, No. 10, pp. 20-31 (Oct. 2000).
Lang, Nicolas et al., “Preconditioning with Transcranial Direct Current Stimulation Sensitizes the Motor Cortex to Rapid-Rate Transcranial Magnetic Stimulation and Controls the Direction of After-Effects,” Biol Psychiatry 2004:56:634-639, 2004 Society of Biological Psychiatry.
Larson, John et al., “Reversal of LTP by theta frequency stimulation,” Brain Research, 600: pp. 97-102 (1993).
Lazar, M. et al., “White Matter Tractography Using Diffusion Tensor Deflection,” Human Brain Mapping, 18:306-321, (2003).
L-DOPA dyskinesias, BioChemistry of PD, http://www.mayo.edu-fdp-pd-info-dyskinesias.htm [Retrieved on Dec. 22, 2005].
Levy et al., “Functional MRI Evidence of Cortical Reorganization in Upper-Limb Stroke Hemiplegia Treated with Constraint-Induced Movement Therapy,” American Journal of Physical Medicine & Rehabilitation, vol. 80, No. 1, pp. 4-7 (2001).
Liepert et al., “Treatment-Induced Cortical Reorganization After Stroke in Humans,” Stroke, Jun. 2000, 31(6):1210-1216.
Malenka, R.C. and Nicoll, R.A., “Long-Term Potenetiation—A Decade of Progress?,” Neuroscience, vol. 285, No. 5435, Issue of Sep. 17, 1999, pp. 1870-1874.
Mansur, C.G. et al., “A sham stimulation-controlled trial of rTMS of the unaffected hemisphere in stroke patients,” Neurology, vol. 64, pp. 1802-1804 (2005).
Martin et al., “Transcranial Magnetic Stimulation as a Complementary Treatment for Aphasia,” Semin Speech Language, vol. 25, pp. 181-191 (2004) Abstract Only- 1 page.
Martinez et al., “Motor hand recovery after stroke Prognostic yield of early transcranial magnetic stimulation,” Electromyogr. Clin. Neurophysiol., Oct.-Dec. 1999, 39(7):405-410.
Meyerson, B.A. et al., “Motor Cortex Stimulation as Treatment of Trigeminal Neuropathic Pain”, Acta Neurochirurgica Supplementum, vol. 58, pp. 150-153 (1993).
Netz et al., “Reorganization of motor output in the non-affected hemisphere after stroke,” Brain, 120, pp. 1579-1586 (1997).
Nitsche, M.A. and Paulus, W., “Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation,” The Journal of Physiology, Sep. 15, 2000, 527(3):633-9.
Nitsche, Michael A. et al. “Facilitation of Implicit Motor Learning by Weak Transcranial Direct Current Stimulation of the Primary Motor Cortex in the Human,” Journal of Cognitive Neuroscience, May 2003, 15(4):619-26, Published by the MIT Press with the Cognitive Neuroscience Institute.
Nitsche, Michael A. et al., “Level of action of cathodal DC opographyn induced inhibition of the human motor cortex,” Dec. 2, 2002, Clinical Neurophysiology 114 (2003) 600-604.
Nudo, Randolph J. et al., “Recovery after damage to motor cortical areas,” Current Opinion in Neurobiology, vol. 9, Issue 6, pp. 740-747, Dec. 1, 1999.
Oliveri et al., “Paired transcranial magnetic stimulation protocols reveal a pattern of inhibition and facilitation in the human parietal cortex,” The Journal of Physiology, Dec. 1, 2000, 529.2, pp. 461-468.
Panchanathan, Sethuraman et al., “Rehabilitation of patients with hemispatial neglect using visual-haptic feedback in Virtual reality environment,” http://www.public.asu.edu-˜tmcdani-publications.htm, 5 pages [Retrieved on Dec. 22, 2005].
Pascual-Leone et al., “Study and Modulation of Human Cortical Excitability With Transcranial Magnetic Stimulation,” Journal of Clinical Neurophysiology, Jul. 1998, 15(4):333-43, Published by Lippincott Williams & Wilkins.
Pascual-Leone et al., “Transcranial magnetic stimulation and neuroplasticity,” Neuropshychologia, Feb. 1999, 37(2):207-17.
Paulus, W, “Supplements to Clinical Neurophysiology,” Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation (Supplements to Clinical Neurophysiology; vol. 56), pp. 249-254, 2003 Elsevier Science, B.V.
Paulus, Walter, “Toward Establishing a Therapeutic Window for rTMS by Theta Burst Stimulation,” Neuron, vol. 45, pp. 181-183 (Jan. 20, 2005).
Penn, Michael, “Stemming Parkinson's,” On Wisconsin Alumni Magazine, Summer 2003, http://www.uwalumni.com-onwisconsin-2003—summer-research.html, 1 page [Retrieved on Dec. 22, 2005].
Rezai, “Neurostimulation,” Neurological Research, vol. 22, No. 3 pp. 235-273 (Apr. 2000).
Robinson, Kenneth R., “The Responses of Cells to Electrical Fields: A Review,” The Journal of Cell Biology, vol. 101, pp. 2023-2027 (Dec. 1985).
Rossi et al., “Effects of Repetitive Transcranial Magnetic Stimulation on Movement-related Cortical Activity in Humans,” Cerebral Cortex, vol. 10, No. 8, pp. 802-808 (Aug. 2000).
Roux et al., “Chronic Motor Cortex Stimulation for Phantom Limb Pain: A Functional Magnetic Resonance Imagining Study: Technical Cast Report,” Neurosurgery, vol. 48, No. 3 (Mar. 2001).
Saitou et al., “Cerebral Blood Volume and Oxygenation Among Poststroke Hemiplegic Patients: Effects of 13 Rehabilitation Tasks Measured by Near-Infrared Spectroscopy,” Arch. Phys. Med. Rehabil., vol. 81 pp. 1348-1356 (Oct. 2000).
Sandkuhler, “Learning and memory in pain pathways,” Pain, Nov. 2000, 88(2):113-18, Elsevier/North-Holland.
Sanes, “The Relation between Human Brain Activity and Hand Movements,” NeuroImage, May 2000, 11(5), pp. 370-374.
Sanes, J. and Donoghue, J.P., “Plasticity and Primary Motor Cortex,” Annual Review of Neuroscience, 2000, 23:393-415.
Schaefer, Pamela W. et al., “Assessing Tissue Viability with MR Diffusion and Perfusion Imaging,” AJNR, 24: pp. 436-443 (Mar. 2003).
Schiene, Klaus et al., “Neuronal Hyperexcitability and Reduction of GABA-Receptor Expression in the Surround of Cerebral Photothrombosis,” Journal of Cerebral Blood Flow and Metabolism, vol. 16, No. 5, pp. 906-914 (1996).
Schiff et al., “A neuromodulation strategy for rational therapy of complex brain injury states,” Neurological Research, vol. 22 pp. 267-272 (Apr. 2000).
SCIRun, Scientific Computing and Imaging Institute. http://www.sofware.sci.utah.edu-scirun.html, 2 pages [Retrieved on Jul. 24, 2005].
Shimizu et al., “Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration,” Tohoku Journal of Experimental Medicine, 189(3):203-11 (Nov. 1999).
Siebner et al., “Lasting cortical activation after repetitive TMS of the motor cortex,” Neurology 54, pp. 956-963 (Feb. 2000).
Stefan et al., “Induction of plasticity in the human motor cortex by paired associative stimulation,” Brain, vol. 123, No. 3, pp. 572-584 (Mar. 2000).
Strangman, Gary et al., “A Quantitative Comparison of Simultaneous BOLD fMRI and NIRS Recordings during Functional Brain Activation,” NeuroImage, vol. 17, pp. 719-731 (2002).
Strangman, Gary et al., “Factors affecting the accuracy of near-infrared spectroscopy concentration calculations for focal changes in oxygenation parameters,” NeuroImage, vol. 18, pp. 865-879 (2003).
Strangman, Gary et al., “Non-Invasive Neuroimaging Using Near-Infrared Light,” Biological Psychiatry, vol. 52, pp. 679-693 (2002).
Strens, Lucy et al., “The Ipsilateral Human Motor Cortex Can Functionally Compensate for Acute Contralateral Motor Cortex Dysfunction,” Current Biology, vol. 13, pp. 1201-1205 (Jul. 15, 2003).
Taga, Gentaro et al., “Brain imaging in awake infants by near-infrared optical topogrpahy,” PNAS, vol. 100, No. 19, pp. 10722-10727 (Sep. 16, 2003).
Tang, Cha-Min et al., “Optical Coherence Tomography of the Human Basal Ganglion,” Deep Brain Stimulation Consortium Meeting Program Book, Sep. 29-30, 2003, Washington DC.
The GES 250 for Dense-Array EEG Research, Electrical Geodesics, Inc., http://www.egi.com/ges250r—n.html, 3 pages [Retrieved on Aug. 25, 2005].
The INVOS Cerebral Oximeter, Somanetics, http://www.somanetics.net/invos.htm, 1 page [retrieved from the internet on Dec. 22, 2005].
Theoret, Hugo et al., “Exploring Paradoxical Functional Facilitation with TMS,” Supplements to Clinical Neurophysiology, vol. 56, pp. 211-219 (2003).
Thomas, Carmen et al., “Do Children with aggressive behavior have temporal lobe changes?” Alasbimn Journal, Year 5, No. 19, 8 pages (Jan. 2003).
Timmermann, Lars et al., “The cerebral oscillatory network of parkinsonian resting tremor,” Brain, vol. 126, pp. 199-212, (2003).
Toronov, Vlad et al., “Near-infrared study of fluctuations in cerebral hemodynamics during rest and motor stimulation: Temporal analysis and spatial mapping,” Medical Physics, vol. 27, No. 4, pp. 801-815 (Apr. 2000).
Tractography, Absolute Astronomy Reference, http://www.absoluteastronomy.com-encyclopedia-T-Tr-Tractography.htm, 2 pages [Retrieved on Jul. 24, 2005].
Tsubokawa, T. et al., “Chronic Motor Cortex Stimulation for the Treatment of Central Pain,” Acta Neurochirurgica, Supplementum. vol. 52, pp. 137-139 (1991).
Tsubokawa, T. et al., “Chronic Motor Cortex Stimulation in Patients with Thalamic Pain,” J. Neurosurg 78:393-401, (Mar. 1993).
Tsubokawa, T. et al., “Treatment of Thalamic Pain by Chronic Motor Cortex Stimulation”, PACE, vol. 14, pp. 131-134 (Jan. 1991).
Tuch, D. et al., “Conductivity Tensor Mapping of the Human Brain Using Diffusion Tensor MRI,” Neurobiology, vol. 98 No. 20, pp. 11697-11701 (Sep. 25, 2001).
Turton et al., “Contralateral and ipsilateral EMG responses to transcranial magnetic stimulation during recovery of arm and hand function after stroke,” Electroencephalography and Clinical Neurophysiology, Aug. 1996, 101(4):316-28, Elsevier.
Turton, A. and Lemon, R.N., “The contribution of fast corticospinal input to the voluntary activation of proximal muscles in normal subjects and in stroke patients,” Exp. Brain Res., Dec. 1999, 129(4):559-572, Springer Berlin / Heidelberg.
Van Der Lee et al., “The Intra- and Interrater Reliability of the Action Research Arm Test: A Practical Test of Upper Extremity Function in Patients With Stroke,” Arch. Phys. Med. Rehabil., vol. 82 pp. 14-19 (Jan. 2001).
Walker-Batson et al., “Amphetamine Paired With Physical Therapy Accelerates Motor Recovery After Stroke,” Stroke, vol. 26, No. 12, pp. 2254-2259 (1995).
Weinand et al., “Cerebral blood flow and temporal lobe epileptogenicity,” J Neurosurg, vol. 86, Feb. 1997, pp. 226-232.
Yokoh, Arika et al., “Intermittent versus continuous brain retraction,” Journal of Neurosurgery, vol. 58, pp. 918-923 (Jun. 1983).
Ziemann et al., “Modulation of Plasticity in Human Motor Cortex after Forearm Ischemic Nerve Block,” The Journal of Neuroscience 18(3):1115-1123 (Feb. 1998).
Related Publications (1)
Number Date Country
20120150262 A1 Jun 2012 US
Provisional Applications (1)
Number Date Country
60217981 Jul 2000 US
Continuations (3)
Number Date Country
Parent 12619188 Nov 2009 US
Child 13399597 US
Parent 11388190 Mar 2006 US
Child 12619188 US
Parent 10350947 Jan 2003 US
Child 11388190 US
Continuation in Parts (2)
Number Date Country
Parent 09978134 Oct 2001 US
Child 10350947 US
Parent 09802808 Mar 2001 US
Child 09978134 US